Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
October 24, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Third Quarter 2022 Financial Results

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also...
May 27, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
March 02, 2020 16:01 ET | Source: FibroGen, Inc

FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
October 23, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer

SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
August 26, 2019 08:30 ET | Source: FibroGen, Inc

Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed...
November 08, 2017 16:02 ET | Source: FibroGen, Inc

FibroGen Reports Third Quarter 2017 Financial Results

Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
June 06, 2016 07:00 ET | Source: FibroGen, Inc.

FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...